Zinnate pills 250mg, 10pcs

Composition

1 tablet contains:

Active ingredients:

cefuroxime 250 mg; Excipients:

MCC,

croscarmellose sodium,

sodium lauryl sulfate,

hydrogenated vegetable oil,

colloidal silicon dioxide,

methyl hydroxypropyl cellulose,

propylene glycol,

methyl parahydroxybenzoate,

propyl parahydroxybenzoate,

opaspray is white.

Pharmacological action

of Cefuroxime axetil is a precursor of cefuroxime, which belongs to the cephalosporin antibiotics of the second generation. Cefuroxime is active against a wide range of pathogens, including beta-lactamase-producing strains. Cefuroxime is resistant to bacterial beta-lactamases, so it is effective against ampicillin-resistant or amoxicillin-resistant strains.

The bactericidal effect of cefuroxime is associated with the suppression of bacterial cell wall synthesis as a result of binding to the main target proteins.

In vitro cefuroxime is active against the following microorganisms:  gram – negative aerobes-Haemophilus influenzae (including ampicillin – resistant strains), Haemophilus parainfluenzae, Moraxella catarrhalis, Neisseria gonorrhoeae (including penicillinase-producing and non-penicillinase-producing strains), Escherichia coli, Klebsiella spp., Proteus mirabilis, Providencia spp., Providencia rettgeri; gram – positive aerobes-Staphylococcus aureus (including penicillinase-producing strains, but excluding methicillin-resistant strains), Staphylococcus epidermidis (including penicillinase-producing strains, but excluding methicillin-resistant strains), Streptococcus pyogenes and other beta-hemolytic streptococci, Streptococcus pneumoniae, Group B Streptococcus (Streptococcus agalactiae); anaerobes-gram-positive and gram-negative cocci (including Peptococcus spp. and Peptostreptococcus spp. ), gram-positive rods (including Clostridium spp., except Clostridium difficile, Propionibacterium spp. ), gram-negative rods (including Bacteroides spp. and Fusobacterium spp. ), gram-negative spirochetes (Borrelia burgdorferi).

The following organisms are not sensitive to cefuroxime: Clostridium difficile, Pseudomonas spp., Campylobacter spp. Acinetobacter calcoaceticus, Listeria monocytogenes, methicillin-resistant strains of Staphylococcus aureus and Staphylococcus epidermidis, Legionella spp., Enterococcus faecalis, Morganella morganii, Proteus vulgaris, Enterobacter spp., Citrobacter spp. Serratia spp. Bacteroides fragilis.

Indications

• bronchitis, pneumonia, sore throat, otitis media, skin and soft tissue
• infections infections of the genitourinary system
• purulent inflammation of the joint and bone
• infections of the female genital organs

Contraindications

Hypersensitivity.

Use with caution in the first trimester of pregnancy and lactation.

Side effects

From the digestive system:  nausea, vomiting, diarrhea; possible temporary increase in the activity of liver enzymes (ALT, AST, LDH), jaundice; cases of pseudomembranous colitis have been described.

From the hematopoietic system:  hemolytic anemia, eosinophilia, neutropenia, thrombocytopenia, leukopenia (sometimes pronounced).

Allergic reactions:  skin rash, pruritus, urticaria, fever, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, serum sickness; in isolated cases-anaphylaxis.

From the central nervous system:  headache.

Other services:  Coombs ‘ positive reaction.

Interaction

Concomitant use of cefuroxime and probenecid resulted in a 50% increase in cefuroxime AUC.

How to take, course of use and dosage

A single dose for adults and children over 12 years of age is usually 250 mg 2 times a day.

For severe infections of the lower respiratory tract-500 mg 2 times a day.

For urinary tract infections,125 mg is prescribed 2 times a day, for pyelonephritis-250 mg 2 times a day.

In the treatment of uncomplicated gonorrhea,1 g is prescribed once.

For Lyme disease – 500 mg 2 times a day for 20 days.

Overdose

Symptoms: disorders of the central nervous system, which are manifested by agitation, convulsions. Treatment: perform symptomatic therapy. Zinnat® is eliminated during hemodialysis and peritoneal dialysis.

Special instructions

With prolonged use of Zinnat, increased growth of resistant microorganisms (Candida, Enterococci, Clostridium difficile) is possible, which may require discontinuation of treatment.

If diarrhea occurs during the use of antibiotics, including Zinnat, one should keep in mind the possibility of developing pseudomembranous colitis.

When treating Lyme disease with Zinnat, the Yarisch-Gersheimer reaction is sometimes noted. This reaction is a direct consequence of the bactericidal action of Zinnat on the causative agent of the disease – the spirochete Borrelia burgdorferi.

Patients should be told that this is a frequent and common, spontaneous consequence of antibiotic treatment for Lyme disease.

Form of production

Tablets

Storage conditions

At a temperature not exceeding 30 °C

Shelf life

3 years

Active ingredient

Cefuroxime

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Indications

Urinary Tract Infections, Pyoderma, Pharyngitis, Urethritis, Sore Throat, Eye Infections, Skin Infections, Boils, Bronchitis, Tonsillitis, Otitis